This article was originally published in The Rose Sheet
The National Advertising Division of the Council of Better Business Bureaus recommends Modern Health Labs modify or discontinue ad claims in an infomercial and Web site for its Scalp Med hair re-growth product because the five statements reviewed in the case were either not supported by evidence or could confuse customers, agency reports. NAD further recommends the advertiser disclose in ads that the principal hair growth ingredient in its product is FDA-approved minoxidil. The case was brought to NAD's attention by competitor Global Vision Products...
You may also be interested in...
Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.
Regulators in high-income countries have a responsibility to help health authorities in low- and medium- income countries develop regulatory frameworks for cell and gene therapy products to ensure these treatments are available to all, asserts the US FDA’s biologics center’s director.
Democratic lawmakers argue the Trump administration’s interpretation of how COVID-19 testing is covered by private insurers runs contrary to the Families First Act and CARES Act. They want the administration to update a FAQ sheet that eliminates certain prerequisites that would qualify patients to be reimbursed for the tests.